1. Home
  2. ESTC vs PTCT Comparison

ESTC vs PTCT Comparison

Compare ESTC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elastic N.V.

ESTC

Elastic N.V.

HOLD

Current Price

$47.49

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$71.91

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTC
PTCT
Founded
2012
1998
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.7B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
ESTC
PTCT
Price
$47.49
$71.91
Analyst Decision
Buy
Buy
Analyst Count
27
17
Target Price
$94.08
$80.65
AVG Volume (30 Days)
1.5M
775.1K
Earning Date
05-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
264.48
EPS
N/A
7.78
Revenue
$1,483,296,000.00
$264,734,000.00
Revenue This Year
$19.06
N/A
Revenue Next Year
$13.42
$19.02
P/E Ratio
N/A
$9.45
Revenue Growth
17.04
36.19
52 Week Low
$42.05
$35.95
52 Week High
$96.07
$87.50

Technical Indicators

Market Signals
Indicator
ESTC
PTCT
Relative Strength Index (RSI) 41.84 57.41
Support Level N/A $69.81
Resistance Level $51.91 $71.77
Average True Range (ATR) 2.45 2.21
MACD 0.07 0.61
Stochastic Oscillator 53.45 78.34

Price Performance

Historical Comparison
ESTC
PTCT

About ESTC Elastic N.V.

Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: